AITD3
MCID: ATM050
MIFTS: 24

Autoimmune Thyroid Disease 3 (AITD3) malady

Categories: Genetic diseases

Aliases & Classifications for Autoimmune Thyroid Disease 3

Aliases & Descriptions for Autoimmune Thyroid Disease 3:

Name: Autoimmune Thyroid Disease 3 54 66 29
Autoimmune Thyroid Disease, Susceptibility to, 3 13
Aitd3 66

Classifications:



External Ids:

OMIM 54 608175
MedGen 40 C1842444

Summaries for Autoimmune Thyroid Disease 3

UniProtKB/Swiss-Prot : 66 Autoimmune thyroid disease 3: A complex autoimmune disorder comprising two related diseases affecting the thyroid: Graves disease and Hashimoto thyroiditis. In both disorders, thyroid-reactive T-cells are formed and infiltrate the thyroid gland. In Graves disease, the majority of the T-cells undergo a Th2 differentiation and activate B-cells to produce antibodies against the TSH receptor, which stimulate the thyroid and cause clinical hyperthyroidism. In contrast, Hashimoto thyroiditis is characterized by Th1 switching of the thyroid-infiltrating T-cells, which induces apoptosis of thyroid follicular cells and clinical hypothyroidism.

MalaCards based summary : Autoimmune Thyroid Disease 3, also known as autoimmune thyroid disease, susceptibility to, 3, is related to progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 5, and has symptoms including thyroiditis An important gene associated with Autoimmune Thyroid Disease 3 is TG (Thyroglobulin). The drugs Selenium and Propylthiouracil have been mentioned in the context of this disorder. Affiliated tissues include thyroid, t cells and b cells.

Description from OMIM: 608175

Related Diseases for Autoimmune Thyroid Disease 3

Diseases in the Autoimmune Thyroid Disease 3 family:

Autoimmune Thyroid Disease 2 Autoimmune Thyroid Disease 1
Autoimmune Thyroid Disease 4

Diseases related to Autoimmune Thyroid Disease 3 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 5 9.8 TG ZFAT

Symptoms & Phenotypes for Autoimmune Thyroid Disease 3

Clinical features from OMIM:

608175

Human phenotypes related to Autoimmune Thyroid Disease 3:

32
id Description HPO Frequency HPO Source Accession
1 thyroiditis 32 HP:0100646

Drugs & Therapeutics for Autoimmune Thyroid Disease 3

Drugs for Autoimmune Thyroid Disease 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Vet_approved Phase 4,Phase 2,Phase 3 7782-49-2
2
Propylthiouracil Approved Phase 4,Phase 3,Phase 2 51-52-5 657298
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
5
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
8
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
9
Ephedrine Approved Phase 4 299-42-3 9294
10
Pseudoephedrine Approved Phase 4 90-82-4 7028
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
12
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
13
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
14
Propranolol Approved, Investigational Phase 4 525-66-6 4946
15 Antioxidants Phase 4,Phase 2,Phase 3
16 Micronutrients Phase 4,Phase 2,Phase 3
17 Protective Agents Phase 4,Phase 2,Phase 3
18 Trace Elements Phase 4,Phase 2,Phase 3
19 Antimetabolites Phase 4,Phase 3
20 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
22 Hormones Phase 4,Phase 2,Phase 3,Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
24 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
27 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
29 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
30 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
31 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
32 Neuroprotective Agents Phase 4,Phase 2,Phase 3
33 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Prednisolone acetate Phase 4,Phase 2,Phase 3
35 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
36 Prednisolone phosphate Phase 4,Phase 2,Phase 3
37 Immunosuppressive Agents Phase 4
38 triamcinolone acetonide Phase 4
39 Triamcinolone diacetate Phase 4
40 Triamcinolone hexacetonide Phase 4
41 Antihypertensive Agents Phase 4,Phase 3
42 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
44 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3
45 Benzalkonium Compounds Phase 4
46 Dinoprost Phase 4
47 Lubricant Eye Drops Phase 4,Phase 2
48 Nasal Decongestants Phase 4
49 Ophthalmic Solutions Phase 4,Phase 2
50 Oxytocics Phase 4

Interventional clinical trials:

(show top 50) (show all 75)
id Name Status NCT ID Phase
1 Selenium Supplementation in Pregnancy Unknown status NCT01465867 Phase 4
2 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4
3 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4
4 Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism Completed NCT00531713 Phase 4
5 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4
6 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4
7 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4
8 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4
9 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4
10 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Recruiting NCT03004209 Phase 4
11 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4
12 Effects of Statins in Graves' Orbitopathy (GO) in Hypercholesterolemic Patients Not yet recruiting NCT03110848 Phase 4
13 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Unknown status NCT02155049 Phase 3
14 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3
15 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3
16 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3
17 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3
18 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3
19 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
20 The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Completed NCT00385697 Phase 2, Phase 3
21 Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Completed NCT00920582 Phase 3
22 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3
23 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3
24 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3
25 Early Levothyroxine Post Radioactive Iodine Active, not recruiting NCT01950260 Phase 2, Phase 3
26 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3
27 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3
28 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Not yet recruiting NCT03131726 Phase 3
29 Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01) Terminated NCT00870818 Phase 2, Phase 3
30 Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Terminated NCT01308437 Phase 3
31 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
32 Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) Completed NCT01551498 Phase 2
33 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2
34 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2
35 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2
36 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2
37 B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease Recruiting NCT02316691 Phase 2
38 Teprotumumab Treatment in Patients With Active Thyroid Eye Disease Active, not recruiting NCT01868997 Phase 2
39 IL-2 in Refractory Autoimmune Encephalitis Not yet recruiting NCT02714959 Phase 1, Phase 2
40 Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated NCT00288522 Phase 2
41 A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Terminated NCT01114503 Phase 2
42 Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy Withdrawn NCT01379196 Phase 1, Phase 2
43 TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease Completed NCT00335062 Phase 1
44 A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects Completed NCT01581463 Phase 1
45 Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients Completed NCT01534169 Phase 1
46 Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study Recruiting NCT02760056 Phase 1
47 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy Recruiting NCT02973802 Phase 1
48 Comparative Study of Different I-131 Doses in Graves' Disease Unknown status NCT02114619
49 Local Triamcinolone Injection in Active Thyroid Orbitopathy Unknown status NCT01280214
50 Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People Unknown status NCT02290704

Search NIH Clinical Center for Autoimmune Thyroid Disease 3

Genetic Tests for Autoimmune Thyroid Disease 3

Genetic tests related to Autoimmune Thyroid Disease 3:

id Genetic test Affiliating Genes
1 Autoimmune Thyroid Disease 3 29

Anatomical Context for Autoimmune Thyroid Disease 3

MalaCards organs/tissues related to Autoimmune Thyroid Disease 3:

39
Thyroid, T Cells, B Cells

Publications for Autoimmune Thyroid Disease 3

Variations for Autoimmune Thyroid Disease 3

ClinVar genetic disease variations for Autoimmune Thyroid Disease 3:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ZFAT ZFAT1, IVS9, A-T single nucleotide variant risk factor
2 TG NM_003235.4(TG): c.5995C> T (p.Arg1999Trp) single nucleotide variant risk factor rs2076740 GRCh37 Chromosome 8, 133984058: 133984058
3 TG NM_003235.4(TG): c.2200T> G (p.Ser734Ala) single nucleotide variant risk factor rs180223 GRCh37 Chromosome 8, 133900252: 133900252
4 TG NM_003235.4(TG): c.3082A> G (p.Met1028Val) single nucleotide variant risk factor rs853326 GRCh37 Chromosome 8, 133909974: 133909974
5 TG NM_003235.4(TG): c.-1623A> G single nucleotide variant risk factor rs180195 GRCh37 Chromosome 8, 133877623: 133877623

Expression for Autoimmune Thyroid Disease 3

Search GEO for disease gene expression data for Autoimmune Thyroid Disease 3.

Pathways for Autoimmune Thyroid Disease 3

GO Terms for Autoimmune Thyroid Disease 3

Sources for Autoimmune Thyroid Disease 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....